MedTrace Logo

Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

NCT00556257 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-05-30

No results posted yet for this study

Summary

A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Cyclosporine

Standard of care

DRUG

CP-690-,550

CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00556257 on ClinicalTrials.gov